Alnylam Q4 2024 Earnings Report

Key Takeaways

Alnylam Pharmaceuticals reported strong revenue growth in Q4 2024, driven by the continued success of AMVUTTRA. The company significantly reduced its net loss YoY while maintaining strong product revenue momentum.

Total Revenue

$593M

Previous year: $440M

+34.9%

EPS

$0.06

Previous year: -$0.77

-107.8%

Gross Margin

82.7%

Operating Margin

-17.7%

Net Margin

-14.1%

Cash and Equivalents

$966M

Previous year: $2.44B

-60.4%

Total Assets

$4.24B

Previous year: $3.83B

+10.7%

Alnylam Revenue

Alnylam EPS

Alnylam Revenue by Segment

Forward Guidance

Alnylam expects strong growth in 2025, with product revenues projected between $2.05B and $2.25B, and aims for non-GAAP profitability.

Positive Outlook

Projected revenue growth of 25-37% YoY.
Strong demand for AMVUTTRA continues to drive sales.
Regulatory decision on Vutrisiran for ATTR-CM expected in March 2025.
Expected milestone payments from Roche collaboration.
Increased R&D pipeline with over 25 programs in development.

Challenges Ahead

Continued net losses despite revenue growth.
High SG&A and R&D expenses impacting profitability.
Regulatory risks associated with pipeline approvals.
Potential market competition in RNAi therapeutics.
Foreign exchange fluctuations may impact revenue growth.